[Jump to the guide](#main) [Boston Care Briefings Questions for a clearer decision](/) Understand - [Start & checklist](/) - [What peptides mean](/briefing/) - [Evidence & status](/briefings/evidence-brief/) Check the care - [Check the person](/briefings/credential-brief/) - [What a visit involves](/briefings/visit-brief/) - [Check the pharmacy](/briefings/pharmacy-brief/) - [Reasons to pause](/briefings/risk-brief/) Plan & pay - [What it costs](/briefings/cost-brief/) - [Coverage & payment](/briefings/coverage-brief/) - [Handling & getting help](/briefings/safety-brief/) - [Printable question sheet](/briefings/question-brief/) [Back to the starting checks](/) Understand the medicine # Ask what the evidence actually covers. Begin with the exact medicine and the aim of care. Then ask whether the evidence concerns that product, that use and people in a situation like yours. At the visit Ask for the answer in plain words. Keep what is still unclear on your list. ## Approval belongs to a product and a use The Food and Drug Administration (FDA) reviews specific medicines for approval. As of September 26, 2026, FDA approval covers named uses of the semaglutide brands Ozempic and Wegovy and the tirzepatide brands Mounjaro and Zepbound. That fact does not apply to every product described as peptide therapy. Ask the person prescribing the medicine which studies support using that product for your condition. Ask what those studies cannot tell you. Open the source notes - [FDA: medicine approval records](https://www.accessdata.fda.gov/scripts/cder/daf/) What that care term means Evidence The information behind a claim, such as a study of a particular treatment. ## An online product listing is not an approval FDA's guidance says that having a National Drug Code (NDC) does not establish approval, as of September 26, 2026. A code or a product listing is not the answer to whether this treatment has been reviewed. Ask to see the exact product's FDA approval record, using the source link here. A badge or a picture of an online product listing does not show that approval. Open the source notes - [FDA: the National Drug Code directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) - [FDA: medicine approval records](https://www.accessdata.fda.gov/scripts/cder/daf/) What that care term means National Drug Code A number identifying a medicine product on a government list. Having that number does not mean the product has FDA approval, as of September 26, 2026. ## A popular name can still lack an approved product For retatrutide, thymosin alpha-1, MOTS-c, epitalon, ipamorelin and BPC-157, FDA's public medicine records contained no file, as of September 26, 2026. These files track requests for medicine approval. Finding no file means there is no approved US product; it does not show that FDA refused a request. Approval records alone do not tell you whether a pharmacy may make a medicine to order. According to FDA, federal law bars preparation to order (compounding) of cagrilintide and retatrutide, as of September 26, 2026. For ipamorelin and thymosin alpha-1, the sources checked did not show a basis for ordinary pharmacies to make them, as of September 26, 2026. If any of these names is in your offer, ask what it is meant to treat. Ask which current rule permits this pharmacy to make it, and keep the written answer before paying. Open the source notes - [FDA: medicine approval records](https://www.accessdata.fda.gov/scripts/cder/daf/) - [FDA: weight-loss medicines and versions made to order](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) What that care term means Compounding Preparing a product to an individual order in place of a ready-made medicine. ## A meeting headline is not permission to make a medicine As of September 26, 2026, an ordinary pharmacy making medicine from raw ingredients must meet federal ingredient rules. When an official drug-quality standard exists for an ingredient, the pharmacy must meet it. Without an official drug-quality standard, the ingredient must be part of an FDA-approved drug. Without either basis, the ingredient must appear on FDA's official ingredient list, called the 503A Bulks List. As of September 26, 2026, FDA's documents showed BPC-157, epitalon and MOTS-c did not meet any of those ingredient rules for ordinary pharmacies. An official account of the July 2026 peptide committee's vote remained unpublished by FDA, as of September 26, 2026. The meeting was set to discuss BPC-157, epitalon and MOTS-c, among other ingredients. FDA staff had advised against adding the meeting's ingredients to that official list, as of September 26, 2026. A committee vote gives FDA advice. FDA must formally change the rules to change the list, as of September 26, 2026. A proposal or a headline about a meeting cannot authorize the pharmacy to prepare that medicine. Ask which current rule allows it. Open the source notes - [FDA: the peptide committee meeting](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) - [FDA: how medicines are made to order](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) What that care term means Advisory committee A group that gives FDA advice. Advice is a step in a process, not the final rule, as of September 26, 2026. Use these Boston briefings to consider peptide care. The site provides guidance; it does not offer clinical care or sell medicines. [Question sheet](/briefings/question-brief/) [Read as text](/briefings/evidence-brief/index.md) [Back to the top](#main)